Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med.380, 45–56 (2019).
Article
CAS
PubMed
Google Scholar
Grupp, S. A., DiNofia, A. M. & Si Lim, S. J. Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Pediatr.BloodCancer68, e29123 (2021).
Google Scholar
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med.377, 2531–2544 (2017).
Article
CAS
PubMed
PubMed Central
Google Scholar
Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet396, 839–852 (2020).
Article
PubMed
Google Scholar
Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med.9, 279–286 (2003).
Article
CAS
PubMed
Google Scholar
Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med.3, 95ra73 (2011).
Article
CAS
PubMed
PubMed Central
Google Scholar
Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer21, 145–161 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science359, 1361–1365 (2018).
Article
CAS
PubMed
Google Scholar
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G. & June, C. H. Engineered cellular immunotherapies in cancer and beyond. Nat. Med.28, 678–689 (2022).
Article
CAS
PubMed
PubMed Central
Google Scholar
Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science375, 877–884 (2022).
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med.382, 545–553 (2020).
Article
CAS
PubMed
PubMed Central
Google Scholar
Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med.387, 2113–2125 (2022).
Article
CAS
PubMed
Google Scholar
Center for Biologics Evaluation and Research (CBER). Approval Letter—Kymriah. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/106989/download (2017).
Center for Biologics Evaluation and Research (CBER). Approval Letter—Yescarta. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/108458/download (2017).
Center for Biologics Evaluation and Research (CBER). Approval Letter—Tecartus. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/140415/download (2020).
Center for Biologics Evaluation and Research (CBER). Approval Letter—Breyanzi. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/145712/download (2021).
Center for Biologics Evaluation and Research (CBER). Approval Letter—CARVYKTI. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/156572/download (2022).
Center for Biologics Evaluation and Research (CBER). Approval Letter—ABECMA. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/147062/download (2021).
Center for Biologics Evaluation and Research (CBER). Approval Letter—Breyanzi. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/159473/download (2022).
Center for Biologics Evaluation and Research (CBER). Approval letter—Yescarta. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/157539/download (2022).
Kourelis, T. et al. Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. J. Clin. Oncol.40, e20021 (2022).
Article
Google Scholar
Al Hadidi, S. et al. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 58, 443–445 (2023).
Ahmed, N. et al. ‘Waitlist mortality’ is high for myeloma patients with limited access to BCMA therapy. Front. Oncol.13, 1206715 (2023).
Article
PubMed
PubMed Central
Google Scholar
Locke, F. L. et al. Real-world impact of time from leukapheresis to infusion (vein-to-vein time) in patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel. Blood140, 7512–7515 (2022).
Article
Google Scholar
Wang, K. et al. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies. Cytotherapy21, 1081–1093 (2019).
Article
CAS
PubMed
Google Scholar
Srai, J. S., Badman, C., Krumme, M., Futran, M. & Johnston, C. Future supply chains enabled by continuous processing—opportunities and challenges. May 20–21 2014 Continuous Manufacturing Symposium. J. Pharm. Sci.104, 840–849 (2015).
Article
CAS
PubMed
PubMed Central
Google Scholar
Abou-el-Enein, M. et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. BloodCancer Discov.2, 408–422 (2021).
CAS
Google Scholar
Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev.4, 92–101 (2017).
Article
CAS
PubMed
Google Scholar
Myles, L. & Church, T. D. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies. Cytotherapy24, 344–355 (2022).
Article
CAS
PubMed
Google Scholar
Papathanasiou, M. M. et al. Autologous CAR T-cell therapies supply chain: challenges and opportunities? CancerGeneTher.27, 799–809 (2020).
CAS
Google Scholar
Harrison, R. P., Ruck, S., Medcalf, N. & Rafiq, Q. A. Decentralized manufacturing of cell and gene therapies: overcoming challenges and identifying opportunities. Cytotherapy19, 1140–1151 (2017).
Article
PubMed
Google Scholar
Alqazaqi, R. et al. Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma. JAMA Netw. Open5, e2228877 (2022).
Article
PubMed
PubMed Central
Google Scholar
Palani, H. K. et al. Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India. Bone Marrow Transplant. 58, 160–167 (2022).
Iancu, E. M. & Kandalaft, L. E. Challenges and advantages of cell therapy manufacturing under good manufacturing practices within the hospital setting. Curr. Opin. Biotechnol.65, 233–241 (2020).
Article
CAS
PubMed
Google Scholar
Benjamin, R. et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol.9, e833–e843 (2022).
Article
CAS
PubMed
Google Scholar
Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet396, 1885–1894 (2020).
Article
CAS
PubMed
Google Scholar
Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med.29, 422–429 (2023).
Article
CAS
PubMed
Google Scholar
Neelapu, S. S. et al. First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. J. Clin. Oncol.38, 8002 (2020).
Article
Google Scholar
Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res.6, 1100–1109 (2018).
Article
CAS
PubMed
PubMed Central
Google Scholar
Ottaviano, G. et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci. Transl. Med.14, eabq3010 (2022).
Article
CAS
PubMed
Google Scholar
Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899–910 (2023).
Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res.32, 995–1007 (2022).
Article
CAS
PubMed
Google Scholar
Lam, C., Meinert, E., Yang, A. & Cui, Z. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation. Cytotherapy23, 433–451 (2021).
Article
CAS
PubMed
Google Scholar
Ran, T., Eichmüller, S. B., Schmidt, P. & Schlander, M. Cost of decentralized CAR T‐cell production in an academic nonprofit setting. Int. J. Cancer147, 3438–3445 (2020).
Article
CAS
PubMed
Google Scholar
Bersenev, A. & Fesnak, A. Place of academic GMP facilities in modern cell therapy. In Cell Reprogramming for Immunotherapy (eds Katz, S. G. & Rabinovich, P. M.) Vol. 2097, 329–339 (Springer, 2020).
Zhu, F. et al. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy20, 394–406 (2018).
Article
CAS
PubMed
Google Scholar
Mock, U. et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy. Cytotherapy18, 1002–1011 (2016).
Article
CAS
PubMed
Google Scholar
Lock, D. et al. Automated, scaled, transposon-based production of CAR T cells. J. Immunother. Cancer10, e005189 (2022).
Article
PubMed
PubMed Central
Google Scholar
Castella, M. et al. Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial. Front. Immunol.11, 482 (2020).
Article
CAS
PubMed
PubMed Central
Google Scholar
Jackson, Z. et al. Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma. Front. Immunol.11, 1941 (2020).
Article
CAS
PubMed
PubMed Central
Google Scholar
Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med.26, 1569–1575 (2020).
Article
CAS
PubMed
Google Scholar
Harrison, R. P., Ruck, S., Rafiq, Q. A. & Medcalf, N. Decentralised manufacturing of cell and gene therapy products: learning from other healthcare sectors. Biotechnol. Adv.36, 345–357 (2018).
Article
PubMed
Google Scholar
Center for Drug Evaluation and Research (CDER). Distributed Manufacturing and Point-of-Care Manufacturing of Drugs https://www.fda.gov/about-fda/reports-budgets-cder/distributed-manufacturing-and-point-care-manufacturing-drugs-discussion-paper (2022).
Chalasani, R., Hershey, T. B. & Gellad, W. F. Cost and access implications of defining CAR-T therapy as a drug. JAMA Health Forum1, e200868 (2020).
Article
PubMed
Google Scholar
U.S. Food & Drug Administration (FDA). FDA Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P’s) Product List https://public4.pagefreezer.com/browse/FDA/06-02-2023T10:15/https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/fda-regulation-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-product-list (2018).
U.S. Food & Drug Administration (FDA). Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use https://www.fda.gov/media/109176/download (2020).
U.S. Food & Drug Administration (FDA). Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception https://www.fda.gov/regulatory-information/search-fda-guidance-documents/same-surgical-procedure-exception-under-21-cfr-127115b-questions-and-answers-regarding-scope (2017).
Nagai, S. Regulatory hurdles for CAR T-cell therapy in Japan. Lancet Haematol.8, e686–e687 (2021).
Article
CAS
PubMed
Google Scholar
U.S. Food & Drug Administration (FDA). Identification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers https://www.fda.gov/media/131911/download (2019).
U.S. Food & Drug Administration (FDA). Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-Derived Products https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstration-comparability-human-biological-products-including-therapeutic-biotechnology-derived (1996).
Better, M., Chiruvolu, V. & Sabatino, M. Overcoming challenges for engineered autologous T cell therapies. CellGeneTher. Insights4, 173–186 (2018).
Google Scholar
U.S. Food & Drug Administration (FDA). Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products https://www.fda.gov/media/156896/download (2022).
Marks, P. & Gottlieb, S. Balancing safety and innovation for cell-based regenerative medicine. N. Engl. J. Med.378, 954–959 (2018).
Article
PubMed
Google Scholar
Marks, P. & Gottlieb, S. Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research on New Policies to Advance Development of Safe and Effective Cell and Gene Therapies https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics (2019).
Medicines & Healthcare products Regulatory Agency (MHRA). Consultation on Point of Care Manufacturing https://www.gov.uk/government/consultations/point-of-care-consultation/consultation-on-point-of-care-manufacturing (2021).
Nizzi, F. Redefining the role of blood establishments as raw material suppliers, manufacturers, and distributors for new cell therapies: the Blood Systems experience. Transfusion56, 29S–31S (2016).
Article
PubMed
Google Scholar
Coppens, D. G. et al. Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. Regen. Med.15, 2015–2028 (2020).
Article
CAS
PubMed
Google Scholar
Coppens, D. G. M. et al. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. Cytotherapy22, 592–600 (2020).
Article
PubMed
Google Scholar
Trias, E., Juan, M., Urbano-Ispizua, A. & Calvo, G. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transplant.57, 156–159 (2022).
Article
PubMed
PubMed Central
Google Scholar
Ortíz-Maldonado, V. et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed/refractory malignancies. Mol. Ther.29, 636–644 (2021).
Article
PubMed
Google Scholar
Therapeutic Goods Administration. Autologous Human Cells and Tissues Products Regulation https://www.tga.gov.au/resources/resource/guidance/autologous-human-cells-and-tissues-products-regulation (2019).
Ivaskiene, T., Mauricas, M. & Ivaska, J. Hospital exemption for advanced therapy medicinal products: issue in application in the European Union Member States. Curr.StemCell Res. Ther.12, 45–51 (2016).
Google Scholar
Cuende, N. et al. The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders’ concerns. Cytotherapy16, 1597–1600 (2014).
Article
PubMed
Google Scholar
The Alliance for Regenerative Medicine. Recommendations for the Use of Hospital Exemption http://alliancerm.org/wp-content/uploads/2020/10/ARM-position-on-HE-final-Oct-2020.pdf (2020).
EFPIA & EBE. Hospital exemption for advanced therapy medicinal products (ATMPs): greater transparency needed in order to improve patient safety and access to ATMPs. https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/10102017-ebe-and-efpia-call-on-the-eu-commission-and-member-states-to-improve-transparency-on-hospital-exemptions-for-advanced-therapies/ (2017).
Cuende, N. et al. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cytotherapy24, 686–690 (2022).
Article
PubMed
Google Scholar
Warkentin, P. I. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT). Cytotherapy5, 299–305 (2003).
Article
CAS
PubMed
Google Scholar
Maus, M. V. & Nikiforow, S. The why, what, and how of the new FACT standards for immune effector cells. J. Immunother. Cancer5, 36 (2017).
Article
PubMed
PubMed Central
Google Scholar
Hort, S. et al. Toward rapid, widely available autologous CAR-T cell therapy—artificial intelligence and automation enabling the smart manufacturing hospital. Front. Med.9, 913287 (2022).
Article
Google Scholar
Blache, U., Popp, G., Dünkel, A., Koehl, U. & Fricke, S. Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nat. Commun.13, 5225 (2022).
Article
CAS
PubMed
PubMed Central
Google Scholar
Soler, M. & Lechuga, L. Boosting cancer immunotherapies with optical biosensor nanotechnologies. Eur. Med. J.4, 124–132 (2019).
Article
Google Scholar
Oh, B.-R. et al. Integrated nanoplasmonic sensing for cellular functional immunoanalysis using human blood. ACSNano8, 2667–2676 (2014).
CAS
Google Scholar
Oh, B.-R. et al. Multiplexed nanoplasmonic temporal profiling of T-cell response under immunomodulatory agent exposure. ACS Sens.1, 941–948 (2016).
Article
CAS
PubMed
PubMed Central
Google Scholar
Raphael, M. P., Christodoulides, J. A., Delehanty, J. B., Long, J. P. & Byers, J. M. Quantitative imaging of protein secretions from single cells in real time. Biophys. J.105, 602–608 (2013).
Article
CAS
PubMed
PubMed Central
Google Scholar
Kurucz, I. et al. Label-free optical biosensor for on-line monitoring the integrated response of human B cells upon the engagement of stimulatory and inhibitory immune receptors. Sens. Actuators B Chem.240, 528–535 (2017).
Article
CAS
Google Scholar
Soler, M. et al. Two-dimensional label-free affinity analysis of tumor-specific CD8 T cells with a biomimetic plasmonic sensor. ACS Sens.3, 2286–2295 (2018).
Article
CAS
PubMed
Google Scholar
Walsh, A. J. et al. Classification of T-cell activation via autofluorescence lifetime imaging. Nat. Biomed. Eng.5, 77–88 (2020).
Article
PubMed
PubMed Central
Google Scholar
Rossoff, J. et al. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood138, 2138–2142 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Jacobson, C. A. et al. Outcomes of patients (Pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B cell lymphoma (R/R LBCL) for expanded access and commercial out-of-specification (OOS) product. Blood136, 2–3 (2020).
Article
Google Scholar
Chong, E. A. et al. CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood134, 1873–1875 (2019).
Article
PubMed
PubMed Central
Google Scholar
U.S. Food & Drug Administration (FDA). Approval Order—CliniMACS CD34 Reagent System https://wayback.archive-it.org/7993/20190208123839/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm382986.htm (2014).
U.S. Food & Drug Administration (FDA). Getting a Humanitarian Use Device to Market https://www.fda.gov/medical-devices/humanitarian-device-exemption/getting-humanitarian-use-device-market (2022).
Priesner, C. et al. Automated enrichment, transduction, and expansion of clinical-scale CD62L+ T cells for manufacturing of gene therapy medicinal products. Hum.GeneTher.27, 860–869 (2016).
CAS
Google Scholar
Lock, D. et al. Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum.GeneTher.28, 914–925 (2017).
CAS
Google Scholar
Blaeschke, F. et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. Cancer Immunol. Immunother.67, 1053–1066 (2018).
Article
CAS
PubMed
Google Scholar
Castella, M. et al. Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions. Mol. Ther. Methods Clin. Dev.12, 134–144 (2019).
Article
CAS
PubMed
Google Scholar
Zhang, W., Jordan, K. R., Schulte, B. & Purev, E. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. DrugDes. Devel.Ther.12, 3343–3356 (2018).
CAS
Google Scholar
Aleksandrova, K. et al. Functionality and cell senescence of CD4/ CD8-selected CD20 CAR T cells manufactured using the automated CliniMACS Prodigy® platform. Transfus. Med.Hemother.46, 47–54 (2019).
Google Scholar
Fernández, L. et al. GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS Prodigy. Front. Immunol.10, 2361 (2019).
Article
PubMed
PubMed Central
Google Scholar
Vedvyas, Y. et al. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci. Rep.9, 10634 (2019).
Article
PubMed
PubMed Central
Google Scholar
Arcangeli, S. et al. Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in cancer patients. Front. Immunol.11, 1217 (2020).
Article
CAS
PubMed
PubMed Central
Google Scholar
Bozza, M. et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci. Adv.7, eabf1333 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Palen, K., Zurko, J., Johnson, B. D., Hari, P. & Shah, N. N. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? Cytotherapy23, 985–990 (2021).
Article
CAS
PubMed
Google Scholar
Glienke, W. et al. GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD2 and releasing inducible IL-18. Front. Immunol.13, 839783 (2022).
Article
CAS
PubMed
PubMed Central
Google Scholar
Joedicke, J. J. et al. Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages. Mol. Ther. Methods Clin. Dev.24, 181–198 (2022).
Article
CAS
PubMed
Google Scholar
Nicod, C. et al. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Curr. Res. Transl. Med.71, 103385 (2023).
CAS
PubMed
Google Scholar
Maschan, M. et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat. Commun.12, 7200 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-023-01981-8